Edition:
India

Aviragen Therapeutics Inc (AVIR.OQ)

AVIR.OQ on NASDAQ Stock Exchange Capital Market

0.58USD
2:29am IST
Change (% chg)

$-0.01 (-0.95%)
Prev Close
$0.59
Open
$0.60
Day's High
$0.60
Day's Low
$0.57
Volume
14,604
Avg. Vol
98,633
52-wk High
$1.48
52-wk Low
$0.44

Latest Key Developments (Source: Significant Developments)

Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Aviragen Therapeutics Inc ::AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA.AVIRAGEN THERAPEUTICS INC- ‍EXPECTS TO REPORT TOP-LINE DATA FROM TRIAL IN Q2 OF 2018​.  Full Article

SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics is superior to Vaxart's proposed transaction
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Aviragen Therapeutics Inc :SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics Inc is superior to Vaxart Inc's proposed transaction - SEC Filing.SC Fundamental Value Fund LP says intends to vote against Vaxart Inc's proposed transaction.SC Fundamental Value Fund LP reports 6.19 percent stake in Aviragen Therapeutics Inc as of November 7.  Full Article

Aviragen Therapeutics Q1 loss per share $0.14
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Aviragen Therapeutics Inc :Aviragen Therapeutics reports first quarter of fiscal year 2018 financial results.Q1 loss per share $0.14.Q1 revenue $100,000.  Full Article

Aviragen Therapeutics to pay Vaxart $1.95 mln, if deal terminated
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Aviragen Therapeutics Inc :On termination of merger under specified circumstances, co required to pay Vaxart termination fee of $1.95 million ​- SEC filing.Anticipates incurring about $0.9 million-$1.7 million in total costs associated with job cuts related to Vaxart deal.Company expects to incur the costs during next two quarters through March 31, 2018​.  Full Article

Aviragen Therapeutics and Vaxart enter into merger agreement
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Aviragen Therapeutics Inc :Aviragen Therapeutics and Vaxart enter into merger agreement.Aviragen Therapeutics Inc - ‍merger will result in a combined company vaxart inc​.Aviragen-‍exchange ratio in deal determined by assigning $60 million in value to Aviragen for financial & clinical assets & $90 million in value for Vaxart's assets​.Aviragen Therapeutics Inc - ‍shares of combined are expected to continue trading on Nasdaq under proposed ticker symbol "VXRT"​.Aviragen Therapeutics Inc - ‍Aviragen will reduce its workforce by six to a total of 10 full-time employees​.Aviragen- ‍on pro forma basis, Vaxart securityholders will own about 60% of combined co, Aviragen securityholders will own about 40% of combined co​.Aviragen Therapeutics Inc - ‍transaction has been approved by board of directors of both companies​.Aviragen Therapeutics Inc - ‍shares of combined are expected to continue trading on Nasdaq under proposed ticker symbol VXRT​.Aviragen-‍Vaxart will be announcing positive results from co's phase 1b open-label, dose-ranging study assessing safety, immunogenicity of VXA-G1.1-NN​.Aviragen Therapeutics Inc - ‍VXA-G1.1-NN met both primary and secondary endpoints for safety and immunogenicity in clinical trial​.Aviragen Therapeutics Inc - ‍phase 2 norovirus challenge study is expected to begin in second half of 2018 for VXA-G1.1-NN​.  Full Article

Aviragen Therapeutics reports Q4 loss per share $0.15
Friday, 1 Sep 2017 

Sept 1 (Reuters) - Aviragen Therapeutics Inc :Aviragen therapeutics reports fourth quarter and fiscal year 2017 financial results.Q4 loss per share $0.15.Q4 revenue $100,000 versus $600,000.Q4 revenue view $667,000 -- Thomson Reuters I/B/E/S.Q4 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Aviragen Therapeutics Inc - ‍ Is actively engaged, with assistance of its financial advisor, in evaluating strategic alternatives​.Aviragen Therapeutics Inc - ‍ Put all activities related to BTA585 program on hold until completion of company's strategic review process​.  Full Article

Aviragen delays further enrollment phase 2A trial for drug to treat RSV infections
Friday, 27 May 2016 

Aviragen Therapeutics Inc : Voluntarily decided to delay further enrollment in phase 2a trial of bta585 for treatment of RSV infections being conducted in U.K . Decision emanated from a lab report from 1 subject showing an increase of a cardiac enzyme level coupled with transient ECG changes . Received verbal communication from FDA that IND for BTA585 has been placed on clinical hold . There are currently no trials of BTA585 being conducted under IND. . More specific written information from FDA concerning clinical hold is expected within 30 days . Reached out to medicines and healthcare products regulatory agency to discuss this event .Aviragen Therapeutics provides update on phase 2a trial of bta585 for the treatment of RSV infections.  Full Article

Biota Pharmaceuticals, Inc completes sale of assets related to its broad spectrum antibiotic program
Thursday, 17 Mar 2016 

Biota Pharmaceuticals, Inc:Saus has completed the sale of assets related to its broad spectrum antibiotic program to a newly formed subsidiary of Spero Therapeutics, LLC.Financial terms of the transaction were not disclosed.  Full Article

Biota Pharmaceuticals Inc announces positive results from phase 1 program for direct acting RSV antiviral BTA585
Friday, 26 Feb 2016 

Biota Pharmaceuticals Inc:Announces positive results from phase 1 program for direct acting RSV antiviral BTA585.  Full Article

BRIEF-Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment

* AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA